Gufic Biosciences Ltd
GUFICBIO
Company Profile
Business description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
Contact
SM House, 11 Sahakar Road
1st to 4th Floor
Vile Parle (East)
MumbaiMH400 057
INDT: +91 2267261000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,926
Stocks News & Analysis
stocks
Coca-Cola earnings: Innovation and brand strength underpin growth
We plan to raise our fair value estimate of Coca-Cola stock.
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,314.80 | 17.10 | -0.18% |
CAC 40 | 8,258.86 | 52.79 | 0.64% |
DAX 40 | 24,330.03 | 71.23 | 0.29% |
Dow JONES (US) | 46,924.74 | 218.16 | 0.47% |
FTSE 100 | 9,426.99 | 23.42 | 0.25% |
HKSE | 25,697.57 | 329.98 | -1.27% |
NASDAQ | 22,953.67 | 36.88 | -0.16% |
Nikkei 225 | 49,372.68 | 56.62 | 0.11% |
NZX 50 Index | 13,306.44 | 71.41 | -0.53% |
S&P 500 | 6,735.35 | 0.22 | 0.00% |
S&P/ASX 200 | 9,026.30 | 14.00 | -0.15% |
SSE Composite Index | 3,899.05 | 17.28 | -0.44% |